{"name":"TauRx Therapeutics Ltd","slug":"taurx-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TRx0237","genericName":"TRx0237","slug":"trx0237","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"TRx0237","genericName":"TRx0237","slug":"trx0237","phase":"phase_3","mechanism":"TRx0237 is a tau aggregation inhibitor.","indications":["Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPWklsUzM1MWV5UG9OVUZ2MDVxU0dFZXNicklodnpHb1g5UkNrT3BneEVkai14VkdVajl5MEtkUTFlWG9EWG9JYVR5Y2dDYzdSSW9IeEVDdmd6U2tVcGF3UndTcDIyYjdrV1dOdUVfWFhlM3psYU5VQXFwb29sczN2WktwRUhGWFVsakFTVG1hbElBejlYR0VIRThKX3E4aTFhd3JYZS1zMnRUcnAxYXZ1blpfNmhsd1RtTlpLNEpsWUNhQWZEWk1MWWx3blN5dU5PZlJERjFxZ001QWNLeEFKcWV4Nks4ZDdickZpMEU1VS1peDhYaGc0?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight - Barchart.com","headline":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUTlBMXJCN0MzODBoT2JGaWdKaVZHSEh0NEY5RS0tXzY1MmlBeGszc2k1UkFDV25LRTlQNW56aVFMeWdMcGNkMGlIYTZXQlFGWURvYjhaRUYtUktSbkNJUy1BSGI5SjZVMkZHeEJmOFRqOThxazJFaUtMUldGWUM4TVdleDV3QnBjTWk3SGI5OU5qaWVRVUE?oc=5","date":"2026-02-12","type":"pipeline","source":"PharmTech.com","summary":"European Biotechs Impacting Treatment of Alzheimer’s Disease - PharmTech.com","headline":"European Biotechs Impacting Treatment of Alzheimer’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNUTc4dEs0elh0dWFYNEZOaHBCSTY3enc5MHlNRTlvdFpWaWIyWkM5eVVkTUhEX0NnZ3RrUkRZTkpnejg0WGJpY2RYZU05ZTRLWldkWE9pN0IxU19TTjQtY2VnakRka2xZQ2V4dWR2UTVRdWI1a1JzN3VzMGVWVGVNWWJlSzRJZDVkZFFsT01JMUFhU21wbDNsaGpGX0k2NDZOR2Rn?oc=5","date":"2025-12-16","type":"deal","source":"BioWorld News","summary":"ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug - BioWorld News","headline":"ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBTQmlqUGYzTnFvZG80bVJYMUxhTVk5eFE5bUNaeXhTUWIzQU9jcDJPUmQzcE43ZVhkcExmdi1VWGJfaklLV0VfaDBodzZGSnZlUmJVYUdRaThKcXk1dXI0aDBZUnZUQzhSd0dOYmZvWUc5dUVWdEJMNnBCRGlDUQ?oc=5","date":"2025-11-24","type":"pipeline","source":"pharmaphorum","summary":"J&J abandons Alzheimer's antibody in setback for tau - pharmaphorum","headline":"J&J abandons Alzheimer's antibody in setback for tau","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQVTJLckpxTXhvUVFYMjVUaW1qUVlwX3FwTnRhTXk4YTZyYzhLMGVRbXRVRWRHNUYxVjZXSElvSEtvdXk0ck9hcEIzVUo5RmtQSmZab2FCQVl3ZzJoLXRxb2h0aEVMendJN1RjYVNJbUgwQXdjZDFSVTRKOWItZ3drT1F0TndJa2tNV1MxcjBvSlNnc0c0OEtYTEJJbUNJUDRQTGw4TlM3NjhydzZqMHJIYzloRWg?oc=5","date":"2025-08-13","type":"pipeline","source":"PR Newswire UK","summary":"Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030 - PR Newswire UK","headline":"Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPd3QyQ0JRbGF1TWJBNGZBTXJRWnV1a1hHVGgwcG5DUUFfMmZGYmlYQnpab3ZBVDhkQlU4cVpOdzZpcHd6NWFPbHhJMkkwcGtDbmQ3c0xUSk1kX055NXN1QzNvbzI3Um1BQ3U2WVlWWWtWUzRZWlBob09CdENuZm4zcGRQdThqbFRZNFNBeXBldVpNZTdWMl9tMmRiMHpHMFA4NnZWblRQTVJVMXhScjRjUXVuUmdBYjFBcDA3djNOaXJ5emNId29xN21VRE16SVk0RDhWcFNfR2NQV3pDUy1fLXBWLWZMRFYyOHYxYzJpa1VEWUtlRVpPNUdSRUxraUZESzhPWEZPdHVCNFRLVTdSbG9icUJaQWhyS050WjNzckRFaWpIYWF3cjVUWjQ4dkZUYTlCRlBadjNadHl4OXJtLXQ5dDJnVmc2?oc=5","date":"2025-07-08","type":"pipeline","source":"GlobeNewswire","summary":"Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire","headline":"Alzheimer’s Therapeutics Market on Upward Trajectory Across","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxNdTlUVV9UQ0M2bmowemt4UVFrZHlSbzRpMlZ0dnFfNVdOaTEwb1lPNnNiaHFYZFV5TVBJclBuT2dnZU9OeXhqV2Vtc2NabVpSZXY2bXdNblFvR2t2Sl93MGF0bkgxbzJCblZhWUxuckZXdTlxZExlQ2RiRGtHakNpU3dqNG5uaG4yNkUwYVVDM3hxVW1fbDdGdUdSRGxGanl3aHd1cmE2cWJuaUhOSlBtc242M2VnWnpFRm9EdGJLeGJNWk5EbWRWb19yWW9ob2g5T2dFRjNINlNRYm1fTG41dmxIWU9WQkxhUlJpVGZXcjY3enRJR1liTVIzcXZjZFVSTFVVbWp2alhuOXVLc1oyZ1dQajZlRWptMTVOTHdyRE02YWV1RWNNWXV3c1pxWjVmMXRjM3pubmthc0p5ZEVvMkpkOWZaZlB3TlE?oc=5","date":"2025-04-29","type":"trial","source":"GlobeNewswire","summary":"Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Phenylketonuria Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPX3V2dDAwbHZ4SUo1UWFYV3M5T3ZMMzBIQURGdE9VdTZYYk9VUVFqMnBwVzl0Wl9ZcFg4LV9zNTI2WnVielJseGU0a3duOW9Pa05Zay1vU1JYeUZnV054TVEwMUxSRlBSRHZndFRZYlBCek1UeU9mcGtodHJGMGgyeUpRUW5QZkJlRUxpVHI0V29hc29uUmROTnZEejc4ZF92LVNqSEZOVHNOaGt4Nk50anZTNmRnYjNNYm5aZWpBYWVzNG53a2FwOHBwWk1nUWI5UEgtM3AzZ28wMFZNM1Zmc3d3?oc=5","date":"2025-04-07","type":"trial","source":"Clinical Trials Arena","summary":"AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator - Clinical Trials Arena","headline":"AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOMnhnNFVIVzBSem8tXzJNSDlFUkxRRDRMYk9DMlVjMm54MFNraVRxekgtZ3VWQ2tGLTRPdXFoNFVHWENVQzFGWGRtWlBvU3hFN3JtbFhwT29WV0lTTXg5anJPVVE4el81WnYxUjgyaVZkdEFRWXBObUdmYmRCaF9DdzNLVVc3MDV0YjcyZkdkZzBzLW1QWTRJR09mZnJ6QlBRbFRtMUx5RFRWQVBEZXBwcFB6MTNwUXZjWXE0d0habFRzczUtazRtWTFTZXhRT1l3dk5sNEh6eEdDS2dmcm5qMG1FNzZSeE0?oc=5","date":"2025-01-08","type":"pipeline","source":"prnewswire.com","summary":"Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight - prnewswire.com","headline":"Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNcFFXT2RKSjYyV1BLeFVTaG9HRXh6NXoteWVoVTFGWldQcGdZak9yVmV0VEItcVp4ajUtaG04YzVRS2szYXhhcUdlZXdUVWxsaENKRjJPQThVejg5dE5PZ1o3Yy16QVdKTFZnSTE0M3BJbXRzTzN6QnVjMXBlQXlzVlVqbG10bi03ZWhialBxN0lieG1KcXU5akgwWElRb1o3dW81ckhyRmJueVlrSXFpdTdYYXVrLVIxOWtPbXdacVcxRGpoNWc?oc=5","date":"2024-07-03","type":"trial","source":"The Clinical Trial Vanguard","summary":"TAURx Submits Extraordinary Application for HMTM as Alzheimer’s Disease Breakthrough - The Clinical Trial Vanguard","headline":"TAURx Submits Extraordinary Application for HMTM as Alzheimer’s Disease Breakthrough","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQUDR4dU01U0xoNDNZYlIwX3hjTEE4SzB2V2Y0NW5OZEhyQUJTTVpGd0tLeEhaR0hydnBhYmNHUjVKVG44MWtaY0dETTBQWml5SlpmRV9GTUNLeklmb21kZ1VzQlB4SUtaYlBhV1kzakVManNsM3BnTFNTYU50c21XSzZKX0xQdEx3T3pJaHYwTERPTjI2N1FmNFc1VXpUam96LS1jcXNZcTVNUkhwUXBuRklDeWtZQzdIbEU4VFpTcmltaU1GUUZzQVVFME9oVmxBcDhPN3pVZnhUdUdPNWJGSGhrUVN1YzlraGNKR2l1ZDBBMFRjLXZ1amZ3RkJydlFLMXBUekp3?oc=5","date":"2024-02-05","type":"trial","source":"businesswire.com","summary":"TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March - businesswire.com","headline":"TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in Marc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSkFVX3lxTFAzSDJ5d25mREI5bHp4NVhUSkJ0VjhRMXBXd0Z1SWRwa002VDVhOGhmcGlJbWVUbEhpbkJVdXVrVGRWb0tIc0ZiOVpB?oc=5","date":"2022-10-10","type":"trial","source":"University of Aberdeen","summary":"Alzheimer's drug trial supported by Aberdeen research shows 'evidence of sustained improvement' - University of Aberdeen","headline":"Alzheimer's drug trial supported by Aberdeen research shows 'evidence of sustained improvement'","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}